PRESTIGE CONSUMER HEALTHCARE INC. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent of $78.26 million for the 12-month period ending 2015-03-31, per its 10-K filed 2015-05-14.
Discontinued › Income Statement › Net Income
us-gaap:IncomeLossFromContinuingOperations · last filed 2015-05-14
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2012-03-31 was -$15.00K, a 100.23% decline year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2011-12-31 was $9.51M, a 343.15% increase year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2011-09-30 was $12.95M, a 13.49% increase year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2011-06-30 was $14.77M, a 60.36% increase year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2015 was $78.26M, a 7.77% increase from fiscal 2014.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2014 was $72.61M, a 10.85% increase from fiscal 2013.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2013 was $65.50M, a 76.03% increase from fiscal 2012.
- PRESTIGE CONSUMER HEALTHCARE INC. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2012 was $37.21M, a 27.53% increase from fiscal 2011.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 3 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 6 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 9 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2015-03-31 | $78.26M 10-K · filed 2015-05-14 | |||
| 2014-03-31 | $72.61M 10-K · filed 2015-05-14 | |||
| 2013-03-31 | $65.50M 10-K · filed 2015-05-14 | |||
| 2012-03-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-05-19 | $9.49M derived: sum of 2 quarters · filed 2014-05-19 | $22.44M derived: sum of 3 quarters · filed 2014-05-19 | $37.21M 10-K · filed 2014-05-19 |
| 2011-12-31 | $9.51M 10-Q · filed 2012-02-09 | $22.46M derived: sum of 2 quarters · filed 2012-02-09 | $37.23M 10-Q · filed 2012-02-09 | $43.64M derived: sum of 4 quarters · filed 2013-05-17 |
| 2011-09-30 | $12.95M 10-Q · filed 2011-11-09 | $27.72M 10-Q · filed 2011-11-09 | $34.13M derived: sum of 3 quarters · filed 2013-05-17 | $36.28M derived: sum of 4 quarters · filed 2013-05-17 |
| 2011-06-30 | $14.77M 10-Q · filed 2011-08-05 | $21.18M derived: sum of 2 quarters · filed 2013-05-17 | $23.33M derived: sum of 3 quarters · filed 2013-05-17 | $34.74M derived: sum of 4 quarters · filed 2013-05-17 |
| 2011-03-31 | $6.41M derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-17 | $8.56M derived: sum of 2 quarters · filed 2013-05-17 | $19.97M derived: sum of 3 quarters · filed 2013-05-17 | $29.18M 10-K · filed 2013-05-17 |
| 2010-12-31 | $2.15M 10-Q · filed 2012-02-09 | $13.56M derived: sum of 2 quarters · filed 2012-02-09 | $22.77M 10-Q · filed 2012-02-09 | |
| 2010-09-30 | $11.41M 10-Q · filed 2011-11-09 | $20.62M 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | $9.21M 10-Q · filed 2011-08-05 | |||
| 2010-03-31 | $32.07M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |